NewAmsterdam Pharma Announces Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients Achieved Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
NewAmsterdam Pharma announced that its Phase 2b dose-finding trial evaluating obicetrapib in Japanese patients achieved its primary endpoint with a statistically significant 45.8% median reduction in LDL-C. The trial also showed favorable safety and tolerability, and the data will enable PMDA regulatory path alignment with the rest of the world.
June 05, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NewAmsterdam Pharma's successful Phase 2b trial of obicetrapib in Japanese patients may positively impact the company's stock price.
The successful Phase 2b trial results indicate that obicetrapib is effective in reducing LDL-C levels in Japanese patients. This achievement may lead to potential approval in Japan, which could positively impact NewAmsterdam Pharma's stock price as it expands its market reach and potential revenue.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100